On Jul. 27, 2020, Emergent BioSolutions announced that it had signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZenecaﾒs COVID-19 vaccine candidate, AZD1222. The agreement is valued at approximately $174 million through 2021 and follows an $87 million contract in Jun. for development services, performance and process qualification, raw materials and an initial capacity reservation.